Pain Management Drugs Market Size - By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine), Indication (Arthritic, Neuropathic, Cancer), Pain Type (Chronic, Acute), Distribution Channel (Hospital, Retail, Online), Global Forecast (2023 – 2032)

Pain Management Drugs Market Size - By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine), Indication (Arthritic, Neuropathic, Cancer), Pain Type (Chronic, Acute), Distribution Channel (Hospital, Retail, Online), Global Forecast (2023 – 2032)

Pain Management Drugs Market Size

Pain Management Drugs Market size was valued to be USD 70.1 billion in 2022 and is expected to reach USD 108.9 billion in 2032 with a CAGR of 4.5% by 2032 due to the rising incidence of chronic diseases, increasing geriatric population who are more prone to chronic pain, and Favorable regulatory scenario. Also, rise in the number of patients for pain management of osteoarthritis, diabetic neuropathy and cancer.
 

Additionally, pharmaceutical companies are investing in R&D in order to discover and develop novel pain management medications. Drug development innovation, such as the introduction of abuse-deterrent formulations and novel mechanisms of action, broadens patients' treatment options.
 

COVID-19 Impact

This pandemic has slowed economic development across a wide range of economies. The COVID-19 pandemic is anticipated to have an influence on the market for pain medication. During the COVID-19 pandemic, there was a major reduction in the number of elective operations. Many non-urgent procedures were rescheduled in order to prioritise resources for Covid-19 patients and lower the risk of infection spread in healthcare facilities.
 

However, the COVID-19 pandemic had a favorable effect on the market due to a potential link between Covid-19 and pain medications. For example, in July 2020, the National Center for Biotechnology Information reported that patients may have lower back discomfort, widespread myalgias, or headaches as early signs of Covid infection. There is growing evidence that SARS-CoV-2 can infiltrate the neurological system, especially in immune compromised patients. According to statistics from April 2022 released by PubMed, it was found that patients with chronic pain in the US and Canada saw a substantial rise in discomfort during the pandemic.
 

Pain Management Drugs Market Trends

The rising prevalence of chronic disorders, increasing healthcare expenditure and investments, increasing geriatric population, and rise in the number of research and development activities, are fuelling the industry development.  
 

The increasing demand for nonsteroidal anti-inflammatory drugs (NSAIDs) and cannabinoids has gained traction in pain management. Research has suggested that cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), may have analgesic properties and can be used to alleviate chronic pain. Drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and certain antidepressant drugs have gained popularity in managing pain. In addition to this, combination of different classes of pain medications to achieve synergistic effects has gained healthcare professional’s attention. This approach can enhance pain relief while potentially reducing the required dosage of individual drugs.
 

Pain Management Drugs Market Analysis

Based on drug class, the pain management drugs market is classified into NSAIDS, anesthetics, anticonvulsants, antimigraine drugs, antidepressant drugs, opioids, non-narcotic analgesics, and other drugs. The opioids segment held the greatest market share of 29.4% in 2022. Opioids have a strong analgesic effect and are highly effective in providing pain relief, especially for severe pain that is not adequately controlled by other medications. Their ability to target opioid receptors in the central nervous system helps to block pain signals and alleviate discomfort.  
 

Based on indication type, the pain management drugs market is categorized into arthritic pain, neuropathic pain, cancer pain, chronic back pain, post-operative pain, migraine, fibromyalgia, bone fracture, muscle sprain/strain, acute appendicitis, and other indications. The neuropathic segment held the largest market share of 19.7% in 2022. Neuropathic pain is a prevalent disease that affects a large number of people globally. It can be caused by a variety of underlying diseases, such as diabetic neuropathy, post-herpetic neuralgia, nerve injuries, and neuropathies linked with disorders such as multiple sclerosis.
 

Based on pain type, the pain management drugs market is bifurcated into chronic pain and acute pain. The chronic pain segment was anticipated to be worth USD 40.4 billion in 2022 and is expected to grow at 4.7% CAGR by 2032. Advances in drug delivery technology and formulation processes have increased the efficacy and convenience of chronic pain treatment medicines. Extended-release formulations, transdermal patches, and new delivery technologies improve pain management and patient compliance.
 

Based on distribution channel, the pain management drugs market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held dominant market share of around 42.6% in 2022 and is expected to grow at a significant pace of 4.4% by 2032. The demand for pain management drugs is substantial due to various acute and chronic pain conditions.
 

North America pain management drugs market accounted is expected to reach USD 42 billion in 2032 with a CAGR of 4.1% by 2032 attributed to the factors such as high incidence of chronic diseases, growing elderly population, and availability of well-developed healthcare infrastructure. North America focuses on technology advances in pain treatment such as novel drug delivery methods, neuromodulation devices such as spinal cord stimulators, and non-invasive treatments such as transcranial magnetic stimulation give alternative treatment choices.
 

Moreover, North America has stringent regulatory frameworks governing the development, approval, and marketing of pain management drugs. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and Health Canada, prioritize patient safety and efficacy. Compliance with regulatory requirements ensures high standards and quality in the industry.
 

Pain Management Drugs Market Share

The prominent players are

• ENDO HEALTH SOLUTIONS INC. (ENDO INTERNATIONAL PLC.)
• Merck & Co., Inc.
• Novartis AG Pfizer, Inc.
• Sanofi S.A.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Abbott Laboratories
• Purdue Pharma L.P.
• GlaxoSmithKline Plc.
• Johnson & Johnson
• F. Hoffmann La Roche Ltd.
   

Pain Management Drugs Market Industry News

• In May 2021, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for pain management. 
   
• In October 2022, Parker Laboratories launched two highly effective topical pain management creams, helix tri-active and helix with CBD, for patients suffering from chronic pain.
   

The pain management drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Drug class

• NSAIDS
• Anesthetics
• Anticonvulsants
• Antimigraine drugs
• Antidepressant drugs
• Opioids
• Non-narcotic analgesics
• Other drugs

By Indication Type

• Arthritic pain
• Neuropathic pain
• Cancer pain
• Chronic back pain
• Post-operative pain
• Migraine
• Fibromyalgia
• Bone fracture
• Muscle sprain/strain
• Acute appendicitis
• Other indications

By Pain Type

• Chronic type
• Acute type

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europ 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa